MXCT Earnings & Financial Statements
MaxCyte, Inc.
$1.01
-$0.01(-0.98%)
33
Overall
60
Value
10
Tech
31
Quality
Market Cap
$105.27M
Volume
172.14K
52W Range
$0.64 - $1.87
Target Price
$4.67
MXCT earnings and financial statements: MaxCyte, Inc.'s income statement, balance sheet and cash flow statement, annual and quarterly.
MXCT Annual Financial Statements
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | $33.03M | $38.63M | $41.29M | $44.26M | $33.89M |
| Cost of revenue | $6.22M | $7.10M | $4.74M | $5.10M | $3.65M |
| Operating income | -$51.90M | -$51.20M | -$48.30M | -$27.36M | -$18.19M |
| EBITDA | -$39.49M | -$32.12M | -$36.26M | -$24.66M | -$17.72M |
| Net income | -$44.63M | -$41.05M | -$37.92M | -$23.57M | -$19.08M |
| EPS (diluted) | $-0.42 | $-0.39 | $-0.37 | $-0.23 | $-0.21 |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Total assets | $202.51M | $239.47M | $268.27M | $286.65M | $284.12M |
| Total liabilities | $31.02M | $33.22M | $36.11M | $32.69M | $21.22M |
| Shareholders’ equity | $171.49M | $206.25M | $232.17M | $253.97M | $262.90M |
| Cash and equivalents | $20.07M | $27.88M | $46.51M | $11.06M | $47.78M |
| Long-term debt | $16.49M | $17.17M | $17.97M | $15.94M | $5.15M |
| Fiscal year | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating cash flow | -$34.41M | -$27.61M | -$21.69M | -$14.78M | -$10.68M |
| Capital expenditure | -$1.77M | -$1.65M | -$3.70M | -$18.48M | -$3.83M |
| Free cash flow | -$36.18M | -$29.26M | -$25.39M | -$33.26M | -$14.51M |
| A | B | C | D | |
|---|---|---|---|---|
| 1 | Symbol | Price | Change | Vol |
| 2 | MXCT | $1.01 | -1.0% | 172.14K |
| 3 | ||||
| 4 | ||||
| 5 | ||||
| 6 |